Tegsedi Mode of Action
Tegsedi targets TTR production in hATTR(1,2)

Mode of Action

Mode of Action

Tegsedi targets TTR production in hATTR(1,2)

Tegsedi targets TTR production in hATTR1,2

Tegsedi reduces the synthesis of TTR protein in the liver through degradation of TTR mRNA, targeting the disease at its source.1,2

  • Tegsedi is a short, 20-base antisense oligonucleotide (ASO) with a sequence complementary to part of the TTR mRNA1
  • Tegsedi binds to and causes degradation of TTR mRNA, inhibiting TTR protein synthesis1,2

Read more
About Tegsedi

About Tegsedi

For your hATTR patients with stage 1 or 2 polyneuropathy, what matters is now

Efficacy

Efficacy

Tegsedi significantly delay disease progression vs placebo1

Safety

Safety

Up to 6 years of experience in clinical trials4

Administration

Administration

Tegsedi is administered as a convenient weekly subcutaneous injection1,2

Tegsedi CONNECT

Tegsedi CONNECT

Empowering independence for people living with hATTR

Prescribing information

Prescribing information

References

mRNA, messenger ribonucleic acid; TTR, transthyretin.
OLE, open-label extension; TTR, transthyretin

  1. Tegsedi Summary of Product Characteristics. April 2021.
  2. Benson MD et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):22–31 (Suppl Appendix).
  3. Brannagan TH, Wang AK, Coelho T, et al. Eur J Neurol. 2020;27(8):1374-1381.
    doi:10.1111/ene.14285
  4. Coelho T et al. Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis. OPR15, 7th Congress of the European Academy of Neurology 2021, 19-22 June 20.